What type of study is this?

September 10, 2025International Journal of Clinical OncologyOpen Access

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

View Full Paper

Ask AI

Bookmark

Long-term follow-up revealed continued efficacy of ibrutinib plus venetoclax in patients with R/R mantle cell lymphoma.
The overall response rate was 83%, with 10 out of 12 patients achieving complete response after treatment.
Treatment involved a ramp-up of venetoclax over five weeks, followed by continuous ibrutinib, showing effectiveness over a median follow-up of 37.2 months.
Common Grade ≥ 3 side effects included neutropenia and leukopenia, with no serious treatment-related complications reported.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 2 trial demonstrated high response rates and prolonged efficacy of ibrutinib plus venetoclax in R/R mantle cell lymphoma patients, indicating a well-tolerated safety profile.

Cite This Study

Goto et al. (2025) studied this question.

synapsesocial.com/papers/68c1824b9b7b07f3a060e9ea https://doi.org/10.1007/s10147-025-02865-4

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 trial demonstrated high response rates and prolonged efficacy of ibrutinib plus venetoclax in R/R mantle cell lymphoma patients, indicating a well-tolerated safety profile.

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

Key Points

Discussion

Implication

Cite This Study

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider